Charming Medical Limited
MCTACharming Medical Limited in brief
Charming Medical Limited is a listed company in the Healthcare sector, based in Hong Kong. Its market value was $446 M on 1 August 2026, which makes it the 13,077th largest listed company in the world and the 203rd largest in Hong Kong on this site. In the year to March 2026 it had sales of $5 M and a net loss of $0 M. Its largest product and service lines by sales in 2026 were Beauty, wellness and postpartum service (94%), Beauty, wellness and postpartum services (94%) and Sales of products (3%). Its shares trade under the symbol MCTA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Charming Medical Limited
Charming Medical Limited was incorporated in the British Virgin Islands as a BVI business company with limited liability on February 28, 2024 under the BVI Act. It is a holding company with no material operations of its own, and it conducts all of its operations in Hong Kong through its Operating Subsidiaries, namely Pilate International Trading Limited, My Beauty Technology Limited, Dream International Trading (Hong Kong) Limited and Choliya Limited, held through intermediate holding company, Beautylab Group Medical Limited.
Our registered office and our registered agent’s office in the BVI are located at Unit 8, 3/F., Qwomar Trading Complex, Blackburne Road, Port Purcell, Road Town, Tortola, BVI, VG1110. Our principal executive offices are located at Units 1803-1806, 18/F, Hang Lung Centre, 2-20 Paterson Street, Causeway Bay, Hong Kong, and our telephone number at this address is +852 2116 1492. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. We maintain a corporate website at https://www.charmingmed.com/. The information contained on, or that can be accessed through, our website is not incorporated by reference into, and does not constitute a part of, this annual report. The SEC maintains a website at www.sec.gov that contains reports and other information regarding issuers, such as us, that file electronically with the SEC.
Charming Medical Limited timeline
- 2024
- 💰Record revenue of $6 millionFY2024, the highest of the 3 years on record.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 21 October 2025; shares registered for exchange trading on 20 October 2025.
Events of Charming Medical Limited from the company's financial years and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 92.7×
- Price / book
- 86.1×
- Free cash flow yield
- -0.3%
- Net margin (TTM)
- -0.4%
- Operating margin
- -0.6%
- Return on equity
- -0.4%
- Liabilities / assets
- 47.5%
- Net debt
- $-5M
- Revenue growth
- -22.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $5M | -22.7% | $-0M | $-0M | -0.4% |
| Mar 2025 | $6M | +3.3% | $1M | $1M | 19.3% |
| Mar 2024 | $6M | — | $1M | $1M | 13.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $-1M | $0M | $-2M | $0.00 | — |
| Mar 2025 | $0M | $0M | $0M | $0.08 | — |
| Mar 2024 | $0M | $0M | $0M | $0.05 | — |
SEC filings
- Nov 9, 20266-KReport of foreign issuer
- Nov 5, 20266-KReport of foreign issuer
- Sep 29, 20266-KReport of foreign issuer
- Jul 30, 202620-FAnnual report (foreign issuer) · period to Mar 2026
- Jul 21, 20266-KReport of foreign issuer
- May 6, 20266-KReport of foreign issuer
- Apr 2, 20266-KReport of foreign issuer
- Mar 31, 20266-KReport of foreign issuer
- Mar 27, 20266-KReport of foreign issuer
- Jan 6, 20266-KReport of foreign issuer
- Nov 28, 20256-KReport of foreign issuer
- Nov 13, 20256-KReport of foreign issuer
Official filings of Charming Medical Limited with the US Securities and Exchange Commission.
Annual results
- Revenue
- $5 M
- Operating income
- $-0 M
- Net income
- $-0 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $5 M
- Total equity
- $5 M
As of March-2026
Top 2 institutional investors in Charming Medical Limited#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 24,249 | 0 (0.00%) | $1 M | Nov 10, 2026 |
| 2 | Geode Capital Management, LLC | 10,752 | 0 (0.00%) | $0 M | Nov 6, 2026 |
Markets and events: Charming Medical Limited#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced · IPO calendar
Trading halts
- 2025-11-12 00:50 UTC, code D, resumed 05:00 UTC
- 2025-11-10 14:33 UTC, code LUDP, resumed 14:38 UTC
- 2025-10-30 14:03 UTC, code LUDP, resumed 14:08 UTC
- 2025-10-21 19:58 UTC, code LUDP, resumed 20:00 UTC
- 2025-10-21 19:13 UTC, code LUDP, resumed 19:18 UTC
Fails to deliver
- : 160 shares at $29.36
- : 224,793 shares at $29.36
- : 1,086 shares at $22.10
- : 818 shares at $20.66
- : 382 shares at $22.60
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Charming Medical Limited scorecard#
Passes 5 of the 12 checks that could be worked out: strongest in financial health (4 of 6), weakest in profitability (1 of 3). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 2
- ✗Revenue grew in the newest year-22.7%Revenue down 22.7% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year0.00 vs 0.08Diluted EPS 0.00 in fiscal 2025 against 0.08 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 3
- ✗Profitable in the newest year-$0 MNet income -$0 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median-0.6%-0.6% against Healthcare's median of -7.7% (674 companies).
- ✗Return on equity above 15%-0.8%-0.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health4 of 6
- ✓Short-term assets cover short-term liabilities1.9×Current ratio 1.89 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.04 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $5 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-1.5×Operating income -1.5 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone58.02Z-score 58.02 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year5.3%Diluted shares up 5.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Charming Medical Limited's statements, beside the median of Healthcare.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -0.6% | -7.7% | |
| Net margin | -0.4% | -8.1% | |
| Return on equity | -0.8% | -36.9% | |
| Revenue growth | -22.7% | 10.2% | |
| Debt to equity | 0.04× | 0.45× | |
| Free cash flow margin | -32.4% | -1.3% |
1of 8on the Piotroski tests of financial strength
- Revenue fell 22.7% against the year before.
- Net loss of $0 million.
- Free cash flow was negative: -$2 million.
- The share count rose 5.3% in the year.
Charming Medical Limited: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 4,808−22.7%100% | 6,222+3.4%100% | 6,015—100% | |
| Cost of revenue | 35+127%0.7% | 16+37.4%0.2% | 11—0.2% | |
| Operating expenses | 4,837+0.1%101% | 4,833−3.5%77.7% | 5,007—83.2% | |
| Operating income | −29−102%−0.6% | 1,389+37.7%22.3% | 1,009—16.8% | |
| Interest and finance income | 73+13.3%1.5% | 64+229%1.0% | 20—0.3% | |
| Interest expense and finance costs | 16−24.3%0.3% | 21−19.9%0.3% | 26—0.4% | |
| Other non-operating income (expense) | 163+252%3.4% | 46—0.7% | −5.4—−0.1% | |
| Income before tax | 133−90.7%2.8% | 1,435+43.0%23.1% | 1,003—16.7% | |
| Income tax | 156−33.9%3.2% | 236+29.9%3.8% | 182—3.0% | |
| Net income including minority interests | −23−102%−0.5% | 1,199+45.9%19.3% | 822—13.7% | |
| Minority interests' share of net income | — | — | 44—0.7% | |
| Net income attributable to shareholders | −23−102%−0.5% | 1,199+54.2%19.3% | 778—12.9% | |
| Earnings per share, basic | 0.00−100%— | 0.08+60.0%— | 0.05—— | |
| Earnings per share, diluted | 0.00−100%— | 0.08+60.0%— | 0.05—— | |
| Shares, weighted average (basic) | 16+5.3%— | 150.0%— | 15—— | |
| Shares, weighted average (diluted) | 16+5.3%— | 150.0%— | 15—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 4,699+475%47.6% | 817−61.2%15.3% | 2,104—— | |
| Receivables | 201−49.1%2.0% | 396—7.4% | — | |
| Inventory | 26−4.4%0.3% | 27—0.5% | — | |
| Current assets | 8,175+143%82.8% | 3,367—62.9% | — | |
| Property, plant and equipment | 607+21.4%6.1% | 500—9.3% | — | |
| Right-of-use (leased) assets | 724+1.9%7.3% | 711—13.3% | — | |
| Non-current assets | 1,694−14.8%17.2% | 1,989—37.1% | — | |
| Total assets | 9,869+84.3%100% | 5,356—100% | — | |
| Accounts payable | 17+394%0.2% | 3.5—0.1% | — | |
| Current liabilities | 4,332−12.5%43.9% | 4,948—92.4% | — | |
| Lease liabilities (non-current) | 356+37.9%3.6% | 258—4.8% | — | |
| Non-current liabilities | 356−0.7%3.6% | 358—6.7% | — | |
| Total liabilities | 4,688−11.7%47.5% | 5,306—99.1% | — | |
| Retained earnings | 97−19.0%1.0% | 119—2.2% | — | |
| Shareholders' equity | 5,181+10421%52.5% | 49—0.9% | — | |
| Total equity | 5,181+10421%52.5% | 49—0.9% | −1,146—— | |
| Total liabilities and equity | 9,869+84.3%100% | 5,356—100% | — | |
| Cash-flow statement | ||||
| Cash from operating activities | −1,216−386%−25.3% | 426+44.2%6.8% | 295—4.9% | |
| Capital expenditure | −340—−7.1% | −288—−4.6% | −211—−3.5% | |
| Cash from investing activities | −179—−3.7% | −2,229—−35.8% | −211—−3.5% | |
| Cash from financing activities | 5,292+915%110% | 521+421%8.4% | 100—1.7% | |
| Exchange-rate effect on cash | −15—−0.3% | −4.6—−0.1% | −11—−0.2% | |
| Report | 20-F | 20-F | 20-F | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Charming Medical Limited sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Beauty, wellness and postpartum services$5 M94%-24%
- Beauty, wellness and postpartum service$5 M94%-24%
- Sales of products$0 M3.4%-24%
- Franchise$0 M2.8%+180%
- Promotional Revenue$0 M2.7%—
- Pre-Opening Service$0 M1.0%—
Source: SEC annual report (XBRL data) · as of Mar 31, 2026
How Charming Medical Limited compares in Healthcare
- Market cap$446 M · higher than 43% of 2,013
- Revenue$5 M · higher than 18% of 1,795
- Net margin-0.4% · higher than 44% of 1,485
- Revenue growth-22.7% · higher than 17% of 1,003
- Price / sales92.7× · lower than 4% of 1,071
- Price / book86.1× · lower than 2% of 1,245
- FCF yield-0.3% · higher than 65% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Charming Medical Limited🇭🇰 | $446 M | — | -0.4% | -22.7% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Charming Medical Limited? Verify and update this profile — free
Show Charming Medical Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.